Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

This study is testing a combination of three targeted therapies — tafasitamab, acalabrutinib, and obinutuzumab — for people who have never been treated for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). These are slow-growing blood cancers, and this drug combination aims to improve treatment without traditional chemotherapy. **You may be eligible if...** - You are 18 or older and have been newly diagnosed with CLL or SLL (never treated before) - Your diagnosis has been confirmed by blood tests or a lymph node biopsy - You meet the standard criteria indicating treatment is needed (e.g., worsening blood counts, enlarged lymph nodes) - You are able to swallow oral medications **You may NOT be eligible if...** - You have already received treatment for CLL or SLL - You have certain heart rhythm problems or other conditions that make these drugs unsafe - You have active, uncontrolled infections - Your organ function does not meet the required levels for safe treatment Talk to your doctor to see if this trial is right for you.